Neoadjuvant Use of Aliya Pulsed Electric Fields with Systemic Therapy in Early-stage Resectable Non-Small Cell Lung Cancer (NSCLC)

A prospective, single-arm, non-randomized, multi-center, open-label study following patients with resectable stage IIB to IIIA non-small cell lung cancer after Pulsed Electric Fields (PEF) ablation who may be candidates for standard of care neoadjuvant use of checkpoint inhibitor (nivolumab) treatment plus platinum doublet chemotherapy.